INCYTE CORP reported second-quarter 2026 results with revenue of $1.67B and diluted EPS of $2.81, driven by product sales growth and higher royalties versus the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$1.67B$1.22B37.7% | Net income²$585.61M$405M44.6% | Diluted EPS³$2.81$2.0437.7% |
¹ Reported as “Total revenues”. ² Reported as “Net income”. ³ Reported as “Diluted income per share”.
Business Highlights
- Total revenues rose to $1.674B in Q2 2026, reflecting strong product sales growth and higher royalties versus the prior year.
- Net sales growth was volume-driven, partially offset by price decreases and higher government rebate accruals.
- Brand momentum included major launches and uptake for JAKAFI XR, OPZELURA expansion, NIKTIMVO, MONJUVI/MINJUVI and ZYNYZ.
- Clinical and regulatory progress: positive Phase 3 results for tafasitamab (frontMIND) and advances for povorcitinib and ruxolitinib cream, with multiple submissions and approvals underway.
- Operational developments: the Vega acquisition for latarcibart closed in July 2026; several late‑stage programs including INCA033989 and INCB161734 are advancing into pivotal trials.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.